Anti-hypertensive Drugs Market

The Anti-hypertensive drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the growing incidence of hypertension among individuals all over the world.

Anti-hypertensive drugs are a type of medication used to treat hypertension (high blood pressure). There are a variety of anti-hypertensive medicines that can lower blood pressure in a variety of ways, avoiding problems such as stroke and myocardial infarction that are linked to high blood pressure. Kidney illness, diabetes, obstructive sleep apnea, and other cardiovascular disorders are the most common recognized causes of hypertension, and the incidence of hypertension has been on the rise in recent years as a result of these factors.

Get Free Sample Report

According to the American college of cardiology's July 2020 the early report from COVID-19 hot spots like Wuhan, Lombardy, and New York City, showed that people with hypertension were among the severely ill and hospitalized COVID-19 patients, which is expected was estimated to boost the market for anti-hypertensive drugs.

Market Trends, Drivers, Restraints, and Opportunities

• Increasing activities by corporate and government organizations is projected to fuel the market during the forecast period.
• Growing awareness of hypertension is key factor propelling the market in the coming years.
• Expiry of patents on numerous key medicines is expected to hinder the market growth.
• Adverse effects associated with hypertension treatment act as major challenge that can restrict the market in the coming years.
• R&D investment and technological advancement in drugs sector is anticipated to create lucrative opportunities for the market players.

Scope of the Anti Hypertensive Drugs Market Report

The report on the anti-hypertensive drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Anti Hypertensive Drugs Market Segment Insights

The diuretics segment is projected to hold a major market share

Based on therapeutics class, the anti-hypertensive drugs market is divided into diuretics, angiotensin converting enzymes inhibitors, angiotensin receptor blockers, beta blockers, alpha blockers, renin inhibitors calcium channel blockers, and others. The diuretics segment is expected to represent a key share of the market during the forecast period. The major mechanism of rise in blood pressure or hypertension in almost all monogenic types of hypertension is salt retention. Diuretics help in the removal of salt and water from the body by causing the kidneys to release more sodium into the urine, lowering blood pressure as the amount of fluid moving through the body lowers. When compared to other therapeutic classes available in the anti-hypertensive medication market, diuretics are the preferred class of therapeutic medicines for the treatment of hypertension.

In addition, the joint national committee on the prevention, detection, evaluation, and treatment of high blood pressure in the United States recommends thiazide-type diuretics as one of the preferred drug treatments for hypertension, whether used alone or in combination with other anti-hypertensive drugs like calcium channel blockers.

Get Free Sample Report

North America is expected to dominate the market

On the basis of regions, the anti-hypertensive drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. Due to extreme incidence of hypertension and illnesses that cause hypertension in the area, North America owns a significant proportion of the anti-hypertensive medicines market and is anticipated to maintain this trend during the forecast period. In addition, factors such as demand for quick and accurate hypertension diagnosis & treatment, identifying people who are prone to the disease, and having a technically advanced healthcare infrastructure are key drivers in the North American anti-hypertension market. The growing prevalence of hypertension in the United States is driving the expansion of the anti-hypertensive drug industry.

According to the National Center for Health Statistics' April 2020 statistics, the prevalence of age-adjusted hypertension in adults in the United States was 45.4 % in adults, 51 % in males, and 39.7 % in women during the 2017-2018 survey. Other aspects include individuals being more aware of hypertension; pharmaceutical firms in the region are launching new products. For example, in November 2018, Dr. Reddy's Laboratories introduced Chlorthalidone tablets, an anti-hypertensive medication, to the US market for the treatment of high blood pressure.

Get Free Sample Report

Segments

The anti-hypertensive drugs market has been segmented on the basis of

Therapeutic class

• Diuretics
• Angiotensin Converting Enzymes Inhibitors
• Angiotensin Receptor Blockers
• Beta Blockers
• Alpha Blockers
• Renin Inhibitors
• Calcium Channel Blockers
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Daiichi Sankyo Company Limited
• Noden Pharma DAC
• Pfizer Inc.
• C.H. Boehringer Sohn AG & KO. KG
• Merck & Co. Inc.

Competitive Landscape

Key players competing in the anti-hypertensive drugs market include Daiichi Sankyo Company Limited, Noden Pharma DAC, Pfizer Inc., C.H. Boehringer Sohn AG & KO. KG, and Merck & Co. Inc.

Some of these players are using several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.